Real-world dosing of omalizumab for chronic spontaneous urticaria

McIntyre, Amanda; Viswanathan, Ravi; Moss, Mark H.; Mathur, Sameer K.

doi:10.1016/j.anai.2019.11.028

Cited by 5 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 43 Another study also demonstrated that personalized omalizumab for long‐term usage (up to 6 years) was safe and effective in treating CIU. 44 Our results were consistent with the previous clinical trials, reaffirming the consistency of the outcomes. While some studies 14 , 31 , 32 , 45 , 46 observed a higher SAE incidence in patients receiving omalizumab, none of the SAEs were determined to be directly caused by omalizumab.…”

Section: Discussionsupporting

confidence: 91%

“…The XTEND‐CIU study confirmed the safety of long‐term omalizumab usage (up to 48 weeks) 43 . Another study also demonstrated that personalized omalizumab for long‐term usage (up to 6 years) was safe and effective in treating CIU 44 . Our results were consistent with the previous clinical trials, reaffirming the consistency of the outcomes.…”

Section: Discussionsupporting

confidence: 87%

“…43 Another study also demonstrated that personalized omalizumab for long-term usage (up to 6 years) was safe and effective in treating CIU. 44 Our results…”

Section: Discussionmentioning

confidence: 63%

See 2 more Smart Citations

Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta‐analysis

Xu,

Yu,

et al. 2024

Skin Research and Technology

View full text Add to dashboard Cite

BackgroundOmalizumab is the only licensed drug that serves as a third‐line treatment for chronic idiopathic urticaria (CIU). The optimum doses of omalizumab remain controversial. Therefore, this study aims to estimate the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.Materials and methodsFour databases were searched from the database's creation to April 8, 2023. Several keywords such as omalizumab and urticarias were used to retrieve related studies. The meta‐analytical outcomes were analyzed in R 4.2.1 software and Stata 15.1 software. Cochrane risk‐of‐bias tool Ver. 2 was used to evaluate the risk of bias in randomized controlled trials (RCTs).ResultsIn total, 2331 patients were included. Five indexes were employed to assess, including weekly Itch Severity Score (ISS7), weekly Hive Severity Score (HSS7), weekly Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and adverse events (AE). A 300 mg dose of omalizumab was the optimum dose to treat CIU, followed by the 150 mg dose. Furthermore, 600 mg of omalizumab only showed a significant difference from the placebo in HSS7. No significant statistical difference was observed in AE. Meta‐regression analysis revealed that time, as a covariate, was statistically significant in the comparison of omalizumab 150 mg with placebo.Conclusion300 mg of omalizumab was the optimum dosage to treat CIU patients, with a 150 mg dose also exhibiting good efficacy. Further studies are required to explore the efficacy and safety of different doses of omalizumab in the treatment of CIU patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 87%

See 1 more Smart Citation

Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta‐analysis

Xu,

Yu,

et al. 2024

Skin Research and Technology

View full text Add to dashboard Cite

show abstract

“…There are only limited studies in the literature reporting how patients with CSU are managed on omalizumab in the longer term and most of these have been performed outside the UK. 4 , 6 , 7 Our pathway is most similar to that described by Giménez Arnau et al ., 8 who also concluded that even patients who do not initially respond to treatment can obtain significant reductions in disease activity if treatment is continued for up to 24 weeks. This is something we have witnessed in practice, with patients appearing to be nonresponders until beyond the fourth dose.…”

Section: Reportsupporting

confidence: 85%

“…Although some omalizumab dose predictors (e.g. body mass indicator, previous ciclosporin use, age), the evidence is limited 6,9 . An increased understanding of the natural CSU fluctuations and biomarker variability may be needed to see if this is transferable to dosing.…”

Section: Reportmentioning

confidence: 99%

Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria

Denman

Smith

Arumugakani

et al. 2022

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

The licensed dose for omalizumab within Europe for chronic spontaneous urticaria (CSU) is 300 mg every 4 weeks, and is based on the most effective dose identified in clinical trials. However, many patients require longer‐term treatment with omalizumab and there is limited guidance on how to manage these patients. We report on a large cohort of 357 patients with CSU who have been treated over a 10‐year period on a personalized dosing regimen. Our results showed a 4% reduction in drug cost for this personalized dosing regimen compared with having all patients on the standard regimen of omalizumab 300 mg every 4 weeks. In addition, by increasing the dose, we were able to treat 22% of patients more effectively, using the principle aim of zero CSU symptoms; prior to this regimen, these patients had been achieving only partial response. Omalizumab doses and frequency should be adjusted depending on clinical response to allow for improved benefits for both patients and healthcare systems.

show abstract

Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management

Huang

et al. 2021

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Real-world dosing of omalizumab for chronic spontaneous urticaria

Cited by 5 publications

References 10 publications

Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta‐analysis

Comparative efficacy and safety of the treatment by Omalizumab for chronic idiopathic urticaria in the general population: A systematic review and network meta‐analysis

Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria

Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management

Contact Info

Product

Resources

About